目的 探讨盐酸川芎嗪注射液联合阿司匹林和阿托伐他汀治疗冠心病心绞痛的临床疗效。方法 选取2014年10月—2016年1月延安大学附属医院收治的冠心病心绞痛患者126例，随机分为对照组（63例）和治疗组（63例）。对照组在一般治疗基础上口服阿司匹林肠溶片，1片/次，1次/d；同时晚餐口服阿托伐他汀钙片，1片/次，1次/d。治疗组患者在对照组的基础上静脉滴注盐酸川芎嗪注射液，2 mL加入生理盐水300 mL中，1次/d。两组患者治疗时间均为15 d。治疗后观察两组患者综合疗效和心电图疗效。比较两组患者每天心绞痛的发作次数与发作持续时间，两组患者总胆固醇（TC）、三酰甘油（TG）和低密度脂蛋白胆固醇（LDL-C）等血脂指标，以及肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）、巨噬细胞移动抑制因子（MIF）、高迁移率族蛋白B1（HMGB1）及超敏C反应蛋白（hs-CRP）等炎性因子水平。结果 治疗后，对照组和治疗组的综合总有效率分别为85.71%、95.24%，两组比较差异有统计学意义（P < 0.05）。治疗后，对照组和治疗组心电图总有效率分别为76.19%、87.30%，两组比较差异有统计学意义（P < 0.05）。治疗后，治疗组患者每天心绞痛发作次数及心绞痛持续时间均明显少于对照组，两组比较差异有统计学意义（P < 0.05）。治疗后，两组患者血清TC、TG和LDL-C的量均明显降低（P < 0.05）；且治疗后治疗组上述指标水平均明显低于对照组（P < 0.05）。治疗后，两组患者TNF-α、IL-6、MIF、HMGB1和hs-CRP含量均明显低于治疗前（P < 0.05）；且治疗后治疗组患者炎性因子水平显著优于对照组（P < 0.05）。结论 盐酸川芎嗪注射液联合阿司匹林和阿托伐他汀治疗冠心病心绞痛临床疗效较好，具有一定的临床推广应用价值。

Objective To explore the clinical effect of Ligustrazine Hydrochloride Injection combined with aspirin and atorvastatin in treatment of coronary heart disease with angina pectoris. Methods Patients (126 cases) with coronary heart disease with angina pectoris in Yan'an University Affiliated Hospital from October 2014 to January 2016 were randomly divided into control (63 cases) and treatment (63 cases) groups. Patients in the control group were po administered with Aspirin Enteric-coated Tablets, 1 tablet/time, once daily. And they were also po administered with Atorvastatin Calcium Tablets at dinner, 1 tablet/time, once daily. Patients in the treatment group were iv administered with Ligustrazine Hydrochloride Injection on the basis of the control group, 2 mL added into normal saline 300 mL, once daily. Patients in two groups were treated for 15 d. After treatment, the comprehensive clinical efficacy and electrocardiogram efficacy were observed, the frequency and duration of angina pectoris, TC, TG, LDL-C, TNF-α, IL-6, MIF, HMGB1, and hs-CRP levels in two groups were compared. Results After treatment, the comprehensive clinical efficacies in the control and treatment groups were 85.71% and 95.24% respectively, and there was difference between two groups (P < 0.05). After treatment, the electrocardiogram efficacies in the control and treatment groups were 76.19% and 87.30% respectively, and there was difference between two groups (P < 0.05). After treatment, the frequency and duration of angina pectoris in the treatment group were significantly less than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the TC, TG, and LDL-C levels in two groups were significantly decreased (P < 0.05). And these blood lipid indexes levels in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the TNF-α, IL-6, MIF, HMGB1, and hs-CRP in two groups significantly decreased (P < 0.05). And these inflammatory factors levels in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion Ligustrazine Hydrochloride Injection combined with aspirin and atorvastatin has a good clinical effect in treatment of coronary heart disease with angina pectoris, which has a certain clinical application value.